Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2016 (2016), Article ID 8029340, 7 pages
http://dx.doi.org/10.1155/2016/8029340
Research Article

Association between Serum Cystatin C and Diabetic Foot Ulceration in Patients with Type 2 Diabetes: A Cross-Sectional Study

1Department of Endocrinology, Diabetic Foot Center, Southwest Hospital, Third Military Medical University, Chongqing 400038, China
2Department of Podiatry, Singapore General Hospital, Singapore 169608
3Department of Surgery, Southern Arizona Limb Salvage Alliance (SALSA), University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
4Department of Endocrinology, Second Affiliated Hospital, Chongqing Medical University, Chongqing 400010, China

Received 9 March 2016; Revised 22 May 2016; Accepted 24 May 2016

Academic Editor: Daisuke Koya

Copyright © 2016 Jie Zhao et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Deng, S. Qiu, G. Yang, and B. Chen, “Exenatide once-weekly injection for the treatment of type 2 diabetes in Chinese patients: current perspectives,” Therapeutics and Clinical Risk Management, vol. 11, pp. 1153–1162, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. D. G. Armstrong and L. A. Lavery, “Diabetic foot ulcers: prevention, diagnosis and classification,” American Family Physician, vol. 57, no. 6, pp. 1325–1338, 1998. View at Google Scholar · View at Scopus
  3. G. H. Skrepnek, J. L. Mills, and D. G. Armstrong, “A diabetic emergency one million feet long: disparities and burdens of illness among diabetic foot ulcer cases within emergency departments in the United States, 2006–2010,” PLoS ONE, vol. 10, no. 8, Article ID 134914, 2015. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Papatheodorou, M. Banach, M. Edmonds, N. Papanas, and D. Papazoglou, “Complications of diabetes,” Journal of Diabetes Research, vol. 2015, Article ID 189525, 5 pages, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Nirantharakumar, M. Saeed, I. Wilson, T. Marshall, and J. J. Coleman, “In-hospital mortality and length of stay in patients with diabetes having foot disease,” Journal of Diabetes and Its Complications, vol. 27, no. 5, pp. 454–458, 2013. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Morbach, H. Furchert, U. Gröblinghoff et al., “Long-term prognosis of diabetic foot patients and their limbs: amputation and death over the course of a decade,” Diabetes Care, vol. 35, no. 10, pp. 2021–2027, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. S. Krolewski, J. H. Warram, C. Forsblom et al., “Serum concentration of cystatin C and risk of end-stage renal disease in diabetes,” Diabetes Care, vol. 35, no. 11, pp. 2311–2316, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. F. Liu, J. Shen, J. Zhao et al., “Cystatin C: a strong marker for lower limb ischemia in Chinese type 2 diabetic patients?” PLoS ONE, vol. 8, no. 7, Article ID e66907, 2013. View at Publisher · View at Google Scholar · View at Scopus
  9. Y. Hu, F. Liu, J. Shen et al., “Association between serum cystatin C and diabetic peripheral neuropathy: a cross-sectional study of a Chinese type 2 diabetic population,” European Journal of Endocrinology, vol. 171, no. 5, pp. 641–648, 2014. View at Publisher · View at Google Scholar · View at Scopus
  10. W. Deng, X. Dong, Y. Zhang et al., “Transcutaneous oxygen pressure (TcPO2): a novel diagnostic tool for peripheral neuropathy in type 2 diabetes patients,” Diabetes Research and Clinical Practice, vol. 105, no. 3, pp. 336–343, 2014. View at Publisher · View at Google Scholar · View at Scopus
  11. American Diabetes Association, “Standards of medical care in diabetes—2010,” Diabetes Care, vol. 33, supplement 1, pp. S11–S61, 2010. View at Publisher · View at Google Scholar
  12. W. J. Jeffcoate, R. M. Macfarlane, and E. M. Fletcher, “The description and classification of diabetic foot lesions,” Diabetic Medicine, vol. 10, no. 7, pp. 676–679, 1993. View at Publisher · View at Google Scholar · View at Scopus
  13. L. X. Zhan, B. C. Branco, D. G. Armstrong, and J. L. Mills Sr., “The Society for Vascular Surgery lower extremity threatened limb classification system based on Wound, Ischemia, and foot Infection (WIfI) correlates with risk of major amputation and time to wound healing,” Journal of Vascular Surgery, vol. 61, no. 4, pp. 939–944, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. F. W. Wagner Jr., “The dysvascular foot: a system for diagnosis and treatment,” Foot and Ankle, vol. 2, no. 2, pp. 64–122, 1981. View at Publisher · View at Google Scholar · View at Scopus
  15. World Health Organization, “International Society of Hypertension Guidelines for the Management of Hypertension,” Journal of Hypertension, vol. 17, no. 2, pp. 151–183, 1999. View at Publisher · View at Google Scholar
  16. C. Bruun, V. Siersma, A. D. Guassora, P. Holstein, and N. de Fine Olivarius, “Amputations and foot ulcers in patients newly diagnosed with type 2 diabetes mellitus and observed for 19 years. The role of age, gender and co-morbidity,” Diabetic Medicine, vol. 30, no. 8, pp. 964–972, 2013. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Al-Rubeaan, M. Al Derwish, S. Ouizi et al., “Diabetic foot complications and their risk factors from a large retrospective cohort study,” PLoS ONE, vol. 10, no. 5, Article ID e0124446, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. E. Pei, J. Li, C. Lu et al., “Effects of lipids and lipoproteins on diabetic foot in people with type 2 diabetes mellitus: a meta-analysis,” Journal of Diabetes and Its Complications, vol. 28, no. 4, pp. 559–564, 2014. View at Publisher · View at Google Scholar · View at Scopus
  19. Y. Yang, T. Østbye, S. B. Tan, Z.-H. Abdul Salam, K. S. Yang, and B. C. Ong, “Risk factors for lower extremity amputation among patients with diabetes in Singapore,” Journal of Diabetes and Its Complications, vol. 25, no. 6, pp. 382–386, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. D. J. Margolis, O. Hofstad, and H. I. Feldman, “Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes,” Diabetes Care, vol. 31, no. 7, pp. 1331–1336, 2008. View at Publisher · View at Google Scholar · View at Scopus
  21. A. S. Levey, C. Becker, and L. A. Inker, “Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kidney disease in adults: a systematic review,” The Journal of the American Medical Association, vol. 313, no. 8, pp. 837–846, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. Y. Ogawa, T. Goto, N. Tamasawa et al., “Serum cystatin C in diabetic patients. Not only an indicator for renal dysfunction in patients with overt nephropathy but also a predictor for cardiovascular events in patients without nephropathy,” Diabetes Research and Clinical Practice, vol. 79, no. 2, pp. 357–361, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. S.-H. Lee, S.-A. Park, S.-H. Ko et al., “Insulin resistance and inflammation may have an additional role in the link between cystatin C and cardiovascular disease in type 2 diabetes mellitus patients,” Metabolism, vol. 59, no. 2, pp. 241–246, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. J. R. Brownrigg, R. J. Hinchliffe, J. Apelqvist et al., “Performance of prognostic markers in the prediction of wound healing or amputation among patients with foot ulcers in diabetes: a systematic review,” Diabetes/Metabolism Research and Reviews, vol. 32, supplement 1, pp. 128–135, 2016. View at Publisher · View at Google Scholar
  25. J. Arpegård, J. Östergren, U. de Faire, L.-O. Hansson, and P. Svensson, “Cystatin C–A marker of peripheral atherosclerotic disease?” Atherosclerosis, vol. 199, no. 2, pp. 397–401, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. H. Yang, C. Wang, M. Guo, Y. Zhou, Z. Feng, and Z. Yin, “Correlations between peroxisome proliferator activator receptor γ, Cystatin C, or advanced oxidation protein product, and atherosclerosis in diabetes patients,” Pathology Research and Practice, vol. 211, no. 3, pp. 235–239, 2015. View at Publisher · View at Google Scholar · View at Scopus
  27. Y. Zhang, Q. Guan, and X. Jin, “Platelet-derived miR-92a downregulates cysteine protease inhibitor cystatin C in type II diabetic lower limb ischemia,” Experimental and Therapeutic Medicine, vol. 9, no. 6, pp. 2257–2262, 2015. View at Publisher · View at Google Scholar · View at Scopus
  28. T. C. Powell, J. P. Donnelly, O. M. Gutiérrez, R. L. Griffin, M. M. Safford, and H. E. Wang, “Cystatin C and long term risk of community-acquired sepsis: a population-based cohort study Epidemiology and Health Outcomes,” BMC Nephrology, vol. 16, article 61, 2015. View at Publisher · View at Google Scholar · View at Scopus
  29. L. S. Dalrymple, R. Katz, B. Kestenbaum et al., “The risk of infection-related hospitalization with decreased kidney function,” American Journal of Kidney Diseases, vol. 59, no. 3, pp. 356–363, 2012. View at Publisher · View at Google Scholar · View at Scopus
  30. E. J. Lew, J. L. Mills, and D. G. Armstrong, “The deteriorating DFU: prioritising risk factors to avoid amputation,” Journal of Wound Care, vol. 24, supplement 2, pp. 31–37, 2015. View at Google Scholar
  31. M. G. Shlipak, R. Katz, M. Cushman et al., “Cystatin-C and inflammatory markers in the ambulatory elderly,” American Journal of Medicine, vol. 118, no. 12, pp. 1416.e25–1416.e31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. A. A. Evangelopoulos, N. G. V. Vallianou, V. Bountziouka et al., “Association between serum cystatin C, monocytes and other inflammatory markers,” Internal Medicine Journal, vol. 42, no. 5, pp. 517–522, 2012. View at Publisher · View at Google Scholar · View at Scopus